Molecular Subtype
Myeloproliferative Neoplasm, BCR-ABL1 Negative
CI-CAN-00003386Explore in graph →
Hematologic94 active trials2 approved drugs8 evidence items
- NCIt
- C198555
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00003386Explore in graph →
Clinical trials
333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | recruiting | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07722611 | A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) | recruiting | Phase 2 / Phase 3 | 380 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | recruiting | Phase 1 / Phase 2 | 150 | Disc Medicine, IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | recruiting | Phase 2 | 25 | University of WashingtonOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07648030 | A Study of Rusfertide in Japanese Adults With Polycythemia Vera | recruiting | Phase 2 | 9 | TakedaINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes | recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07232290 | Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera | recruiting | Phase 2 | 60 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07128381 | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | recruiting | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07612280 | Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis | recruiting | Phase 1 / Phase 2 | 30 | Jubilant Therapeutics Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05835466 | Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | recruiting | Phase 2 | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06063486 | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | recruiting | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation(ACCELERATE) | recruiting | Phase 2 | 358 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05123365 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 27 | University of California, IrvineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | recruiting | Phase 2 | 216 | City of Hope Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04644211 | Ruxolitinib in Thrombocythemia and Polycythemia Vera | recruiting | Phase 2 | 60 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06541249 | MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial(TREATMORE) | recruiting | Phase 2 | 54 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05870475 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV(PV) | recruiting | Phase 2 | 94 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 3, 2024 | clinicaltrials |
Data updated 50 minutes agoSource updated Sep 30, 2026source: clinicaltrials